Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Last trade$3.90
Day change-$0.29 (-6.92%)
Day range$3.87 – $4.40
Volume3,152,989
Market cap$934M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$934.34M
Price / earnings
—
Price / book
110.74×
Price / sales
132.32×
EV / sales
124.55×
EV / EBITDA
-5.02×
Profitability
Earnings per share
-$0.79
Return on assets
-82.46%
Return on equity
-2,090.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.19×
Quick ratio
1.19×
Cash ratio
1.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$158.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRME, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$4.21M
$1.15M
$856K
$838K
$1.23M
$1.12M
$1.45M
$2.18M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$4.21M
$1.15M
$856K
$838K
$1.23M
$1.12M
$1.45M
$2.18M
Selling, general and administrative
$10.02M
$11.04M
$17.41M
$14.74M
$11.21M
$13.12M
$13.28M
$12.3M
Research and development
$34.12M
$33.4M
$34.11M
$34.71M
$43.99M
$41.38M
$40.56M
$34.1M
Total operating expenses
$44.14M
$44.44M
$51.51M
$49.45M
$55.2M
$54.49M
$53.85M
$46.41M
Operating income
-$39.93M
-$43.29M
-$50.65M
-$48.61M
-$53.97M
-$53.38M
-$52.39M
-$44.22M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$39.04M
-$42.11M
-$49.12M
-$46.08M
-$50.58M
-$52.59M
-$51.89M
-$42.28M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$39.04M
-$42.11M
-$49.12M
-$46.08M
-$50.58M
-$52.59M
-$51.89M
-$42.28M
Net income attributable to common shareholders
-$39.04M
-$42.11M
-$49.12M
-$46.08M
-$50.58M
-$52.59M
-$51.89M
-$42.28M
EBITDA
-$38.17M
-$41.5M
-$48.8M
-$46.73M
-$52.09M
-$51.51M
-$50.69M
-$42.51M
Basic earnings per share
-$0.22
-$0.24
-$0.28
-$0.26
-$0.32
-$0.41
-$0.40
-$0.32
Diluted earnings per share
-$0.22
-$0.24
-$0.28
-$0.26
-$0.32
-$0.41
-$0.40
-$0.32
Recent news
Company coverage with links to the original publishers.
Prime Medicine (PRME) reported a quarterly loss of $0.22 per share, beating consensus estimates of $0.23 loss by 4.35%, but missed revenue expectations with $4.21 million versus the consensus estimate, down 25.8%. The stock has outperformed the S&P 500 by 12.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Absci Corporation (ABSI) reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.15 loss by 13.33%. Revenue came in at $0.3 million, significantly missing estimates by 88.43%. The company has failed to beat consensus estimates for four consecutive quarters. Despite a 190% year-to-date gain, ABSI received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on gene editing therapies, announced a public offering of 35.7 million shares at $3.50 per share, expected to raise approximately $125 million. The offering is expected to close on November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs serving as joint book-running managers.
Prime Medicine (PRME) shares jumped 23.2% to $5.36 following FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency and progress in its gene-editing pipeline. The company is expected to report a quarterly loss of $0.23 per share with revenues up 361.6% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, the stock carries a Zacks Rank #3 (Hold) rating, suggesting caution about sustained momentum.
Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 10, 2019
$0.80
Sep 12, 2019
recurring
Jun 14, 2019
$0.20
Jun 28, 2019
recurring
Dec 18, 2018
$0.2133
Dec 31, 2018
recurring
Sep 14, 2018
$0.2327
Sep 28, 2018
recurring
Jun 21, 2018
$0.1457
Jun 29, 2018
recurring
Stock splits
Historical share-structure events and their execution dates.